These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21197522)

  • 1. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines.
    Beer KR; Boyd C; Patel RK; Bowen B; James SP; Brin MF
    J Drugs Dermatol; 2011 Jan; 10(1):39-44. PubMed ID: 21197522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
    Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
    Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
    Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
    Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
    Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
    Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
    Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
    Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
    Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study.
    Stotland MA; Kowalski JW; Ray BB
    Plast Reconstr Surg; 2007 Oct; 120(5):1386-1393. PubMed ID: 17898617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA treatment of moderate to severe glabellar lines in Chinese subjects after laser therapy: A prospective, open-label, noncomparative study.
    Wu Y; Lu Z; Xie Y; Zhang W; Chen X; Shi Y; Li Q; Halstead M; Rogers JD; Silberberg M
    J Cosmet Laser Ther; 2018 Oct; 20(5):278-286. PubMed ID: 29498553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.
    Glogau R; Kane M; Beddingfield F; Somogyi C; Lei X; Caulkins C; Gallagher C
    Dermatol Surg; 2012 Nov; 38(11):1794-803. PubMed ID: 23106853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.
    Rivkin AZ; Ogilvie P; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2020 Jan; 46(1):50-60. PubMed ID: 30829771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
    Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
    Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
    Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.